ArticleAnnals of hematology2011
Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival.
Article in Annals of hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Machine learning prediction of tuberculosis mortality: a comparative analysis of random survival forest and cox regression models.BMC infectious diseases · 2026Article
- Prognostic value of the Controlling Nutritional Status score in patients with newly diagnosed multiple myeloma.American journal of translational research · 2024Article
- A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients.Clinical and experimental medicine · 2023Article
- Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.Frontiers in oncology · 2022Review
- MRI-Based Bone Marrow Radiomics Nomogram for Prediction of Overall Survival in Patients With Multiple Myeloma.Frontiers in oncology · 2021Article
- [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- A rare case of spontaneous tumor lysis syndrome in multiple myeloma.Journal of community hospital internal medicine perspectives · 2020Article
- PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma.BioMed research international · 2020Article
- A centromere-associated gene score for rapid determination of risk in multiple myeloma.American journal of translational research · 2020Article
- Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology.PharmacoEconomics · 2019Article
- A comparison of landmark methods and time-dependent ROC methods to evaluate the time-varying performance of prognostic markers for survival outcomes.Diagnostic and prognostic research · 2019Article
- A risk-based measure of time-varying prognostic discrimination for survival models.Biometrics · 2017Article
- High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma.Oncotarget · 2017Article
- Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma.The Korean journal of internal medicine · 2017Article
- Observational
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Article
- The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.The Korean journal of internal medicine · 2015Article
- Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.Haematologica · 2015Article
- Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.Haematologica · 2014Article
- Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) imaging of multiple myeloma: initial clinical efficiency results.European radiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Multiple myeloma (MM) survival plots usually display steeper initial and shallower subsequent slopes reflecting differences in disease biology and likely prognostic factors (PF). S9321 trial was selected to determine PF operative at baseline and subsequent 3, 4, 5, and 7-year landmarks (LM-0, LM-3, LM-4, LM-5, and LM-7). With a median follow-up of 8.2 years, survival was similar in transplant and standard therapy arms, justifying data pooling. Median survival for 775 eligible patients is 48 months. According to proportional hazards models, seven of 12 investigated baseline variables retained independent significance for LM-0, of which only two (beta-2-microglobulin and age) extended out to LM-7; the remaining five comprised features of disease aggressiveness (lactate dehydrogenase, calcium, platelet count, C-reactive protein) and host co-morbidity (performance status). Our observations of LM dependency of PF can be exploited toward advancing myeloma therapy by stratifying patients according to whether early or late portions of the survival history are being targeted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.